Skip to main content
. Author manuscript; available in PMC: 2015 Jul 27.
Published in final edited form as: Cancer Clin Oncol. 2012 Nov;1(2):49–80. doi: 10.5539/cco.v1n2p49

Figure 5.

Figure 5

Relative cytotoxic anti-neoplastic potency of benzimidazole tubulin/microtubule inhibitors against chemotherapeutic-resistant mammary adenocarcinoma. Legend: (◆) albendazole; (▲) flubendazole; and (■) mebendazole. Mammary adenocarcinoma (SKBr-3) monolayer populations were incubated with individual benzimidazole tubulin/microtubule inhibitors for 72-hours and cytotoxicity measured as a function of MTT cell vitality stain intensity (absorbance at 570 nm) relative to matched negative reference controls.